Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel

Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses an enormous challenge to the medical system, especially the lack of safe and effective COVID-19 treatment methods, forcing people to look for drugs that may have therapeutic effects as...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of pharmacology 2021-02, Vol.893, p.173813-173813, Article 173813
Hauptverfasser:	Zequn, Zheng, Yujia, Wu, Dingding, Qian, Jiangfang, Lian
Format:	Artikel
Sprache:	eng
Schlagworte:	Azithromycin - adverse effects Azithromycin - therapeutic use Chloroquine - adverse effects Chloroquine - therapeutic use COVID-19 COVID-19 - complications COVID-19 - drug therapy Drug Combinations Drugs ERG1 Potassium Channel - drug effects hERG channel Humans Hydroxychloroquine - adverse effects Hydroxychloroquine - therapeutic use Long QT syndrome (LQTS) Long QT Syndrome - chemically induced Long QT Syndrome - epidemiology Lopinavir - adverse effects Lopinavir - therapeutic use Off-Label Use QT interval Ritonavir - adverse effects Ritonavir - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!